Oncotelic Therapeutics (OTLC) Short Interest Ratio & Short Volume $0.06 0.00 (-0.32%) As of 05/22/2025 03:52 PM Eastern Add Compare Share Share Short Interest Stock AnalysisChartHeadlinesSEC FilingsShort InterestBuy This Stock Oncotelic Therapeutics Short Interest DataOncotelic Therapeutics (OTLC) has a short interest of 54,300 shares. This marks a -13.54% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.4, indicating that it would take 0.4 days of the average trading volume of 123,346 shares to cover all short positions.Current Short Interest54,300 sharesPrevious Short Interest62,800 sharesChange Vs. Previous Month-13.54%Dollar Volume Sold Short$2,905.05Short Interest Ratio0.4 Days to CoverLast Record DateApril 30, 2025Outstanding Shares408,292,000 sharesPercentage of Shares Shorted0.01%Today's Trading Volume24,678 sharesAverage Trading Volume123,346 sharesToday's Volume Vs. Average20% Short Selling Oncotelic Therapeutics? Sign up to receive the latest short interest report for Oncotelic Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartOTLC Short Interest Over TimeOTLC Days to Cover Over TimeOTLC Percentage of Float Shorted Over Time Oncotelic Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202554,300 shares $2,905.05 -13.5%N/A0.4 $0.05 4/15/202562,800 shares $3,234.20 +307.8%0.0%0.2 $0.05 3/31/202515,400 shares $1,001.00 -44.0%0.0%0.1 $0.07 3/15/202527,500 shares $1,281.50 -57.0%0.0%0.1 $0.05 2/28/202563,900 shares $2,524.05 +15,875.0%0.0%0.4 $0.04 2/15/2025400 shares $15.96 -77.8%0.0%0 $0.04 1/31/20251,800 shares $54.54 +350.0%N/A0 $0.03 1/15/2025400 shares $13.76 -95.4%N/A0 $0.03 12/31/20248,600 shares $301.00 +230.8%N/A0 $0.04 12/15/20242,600 shares $78.00 +18.2%N/A0 $0.03 Get the Latest News and Ratings for OTLC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Oncotelic Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/30/20242,200 shares $70.18 -94.9%N/A0 $0.03 11/15/202443,400 shares $1,297.66 +137.2%N/A0.1 $0.03 10/31/202418,300 shares $590.18 -62.1%N/A0 $0.03 10/15/202448,300 shares $1,724.31 +11,975.0%N/A0 $0.04 9/30/2024400 shares $8.40 -80.0%N/A0 $0.02 9/15/20242,000 shares $42.40 -59.2%N/A0 $0.02 8/31/20244,900 shares $111.23 +1,125.0%N/A0 $0.02 8/15/2024400 shares $8.24 No ChangeN/A0 $0.02 7/31/2024400 shares $11.20 -98.2%N/A0 $0.03 7/15/202422,000 shares $572.00 +266.7%N/A0.1 $0.03 6/30/20246,000 shares $195.00 +1,400.0%N/A0 $0.03 6/15/2024400 shares $15.72 -83.3%N/A0 $0.04 5/31/20242,400 shares $89.04 +500.0%N/A0 $0.04 5/15/2024400 shares $14.40 -77.8%N/A0 $0.04 4/30/20241,800 shares $71.91 -84.2%N/A0 $0.04 4/15/202411,400 shares $468.54 +2,750.0%N/A0.1 $0.04 3/31/2024400 shares $14.39 -89.7%N/A0 $0.04 3/15/20243,900 shares $144.69 -75.2%N/A0.1 $0.04 2/29/202415,700 shares $554.21 -90.9%N/A0.1 $0.04 2/15/2024172,400 shares $6,637.40 +34.8%N/A0.9 $0.04 1/15/2024111,900 shares $4,420.05 +27,875.0%N/A1.2 $0.04 12/31/2023400 shares $15.30 No ChangeN/A0 $0.04 12/15/2023400 shares $15.76 No ChangeN/A0 $0.04 11/30/2023400 shares $16.28 -97.6%N/A0 $0.04 11/15/202316,700 shares $542.75 -58.2%N/A0 $0.03 10/31/202339,900 shares $1,312.71 +66.3%N/A0.1 $0.03 10/15/202324,000 shares $816.00 +1,400.0%N/A0.1 $0.03 9/30/20231,600 shares $49.60 -95.4%N/A0 $0.03 9/15/202334,500 shares $1,086.75 -52.7%N/A0.1 $0.03 8/31/202372,900 shares $1,909.98 +138.2%N/A0.2 $0.03Trump’s treachery (Ad)Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.Millions of Americans are about to be wiped out, while others could make a fortune… click here to ma 8/15/202330,600 shares $703.80 -4.7%N/A0.3 $0.02 7/31/202332,100 shares $767.19 -50.3%N/A0.1 $0.02 7/15/202364,600 shares $1,627.92 +12.0%N/A0.1 $0.03 6/30/202357,700 shares $1,442.50 +1,054.0%N/A0 $0.03 6/15/20235,000 shares $150.00 -79.8%N/A0 $0.03 5/31/202324,700 shares $768.17 +6,075.0%N/A0.1 $0.03 5/15/2023400 shares $14.76 -55.6%N/A0 $0.04 4/30/2023900 shares $37.80 +125.0%N/A0 $0.04 4/15/2023400 shares $20.40 -99.1%N/A0 $0.05 3/31/202342,900 shares $2,037.75 +164.8%N/A0.3 $0.05 3/15/202316,200 shares $920.16 No ChangeN/A0.1 $0.06 2/28/202316,200 shares $891.00 -57.7%N/A0.1 $0.06 2/15/202338,300 shares $2,106.50 +137.9%N/A0.1 $0.06 1/31/202316,100 shares $821.10 -68.2%N/A0.1 $0.05 1/15/202350,700 shares $2,940.60 +53.6%N/A0.2 $0.06 12/30/202233,000 shares $1,485.00 +11.9%N/A0.1 $0.05 12/15/202229,500 shares $1,416.00 +2,358.3%N/A0.1 $0.05 11/30/20221,200 shares $70.32 -86.8%N/A0 $0.06 11/15/20229,100 shares $682.50 -65.5%N/A0.1 $0.08 10/31/202226,400 shares $1,188.00 -58.8%N/A0 $0.05 10/15/202264,000 shares $3,744.00 -49.7%N/A0.2 $0.06 9/30/2022127,200 shares $8,522.40 +4,286.2%N/A0.3 $0.07 9/15/20222,900 shares $205.90 -62.8%N/A0 $0.07 8/31/20227,800 shares $630.24 -77.5%N/A0 $0.08 8/15/202234,600 shares $2,899.48 -51.1%N/A0.1 $0.08 7/31/202270,700 shares $7,777.00 +288.5%N/A0.2 $0.11 7/15/202218,200 shares $1,820.00 -33.3%N/A0 $0.10 6/30/202227,300 shares $4,641.00 +320.0%N/A0 $0.17 6/15/20226,500 shares $812.50 +14.0%N/A0 $0.13 5/31/20225,700 shares $1,227.21 +119.2%N/A0 $0.22 5/15/20222,600 shares $507.00 -69.8%N/A0 $0.20 4/30/20228,600 shares $1,857.60 +65.4%N/A0 $0.22 4/15/20225,200 shares $1,196.78 +13.0%N/A0 $0.23 3/31/20224,600 shares $1,054.78 -41.0%N/A0 $0.23 3/15/20227,800 shares $1,704.30 -71.6%N/A0 $0.22 2/28/202227,500 shares $6,817.25 +97.8%N/A0.1 $0.25 2/15/202213,900 shares $2,780.00 +157.4%N/A0.1 $0.20 1/31/20225,400 shares $864.00 +1,250.0%N/A0 $0.16 1/15/2022400 shares $70.50 -95.1%N/A0 $0.18 12/31/20218,100 shares $1,359.18 -30.2%N/A0 $0.17 12/15/202111,600 shares $1,914.00 -80.3%N/A0 $0.17 11/30/202158,800 shares $7,938.00 +429.7%N/A0.1 $0.14 11/15/202111,100 shares $1,276.50 -74.5%N/A0 $0.12 10/29/202143,500 shares $5,659.35 +42.6%N/A0.2 $0.13 10/15/202130,500 shares $3,583.75 +682.1%N/A0.1 $0.12 9/30/20213,900 shares $565.50 -51.3%N/A0 $0.15 9/15/20218,000 shares $1,050.40 +90.5%N/A0 $0.13 8/31/20214,200 shares $579.60 +2.4%N/A0 $0.14 8/13/20214,100 shares $512.50 -86.2%N/A0 $0.13 7/30/202129,800 shares $4,619.00 +684.2%N/A0.1 $0.16URGENT: Someone's Moving Gold Out of London... (Ad)People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. Go here to learn about my Top Four picks for the coming bull mania. 7/15/20213,800 shares $672.60 -83.0%N/A0 $0.18 6/30/202122,300 shares $0.00 +214.1%N/A0.1 $0.00 OTLC Short Interest - Frequently Asked Questions What is Oncotelic Therapeutics' current short interest? Short interest is the volume of Oncotelic Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 54,300 shares of OTLC short. Learn More on Oncotelic Therapeutics' current short interest. Is Oncotelic Therapeutics' short interest increasing or decreasing? Oncotelic Therapeutics saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 54,300 shares, a drop of 13.5% from the previous total of 62,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Oncotelic Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Oncotelic Therapeutics: Oramed Pharmaceuticals Inc. (1.60%), Lexeo Therapeutics, Inc. (13.02%), Xtant Medical Holdings, Inc. (0.04%), Coherus BioSciences, Inc. (28.09%), Corbus Pharmaceuticals Holdings, Inc. (17.54%), Pliant Therapeutics, Inc. (8.39%), Ventyx Biosciences, Inc. (11.55%), Senti Biosciences, Inc. (3.18%), Galectin Therapeutics Inc. (19.42%), Adagene Inc. (0.11%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks. What does it mean to sell short Oncotelic Therapeutics stock? Short selling OTLC is an investing strategy that aims to generate trading profit from Oncotelic Therapeutics as its price is falling. OTLC shares are trading down $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Oncotelic Therapeutics? A short squeeze for Oncotelic Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of OTLC, which in turn drives the price of the stock up even further. How often is Oncotelic Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OTLC, twice per month. The most recent reporting period available is April, 30 2025. More Short Interest Resources from MarketBeat Related Companies Oramed Pharmaceuticals Short Interest Lexeo Therapeutics Short Interest Xtant Medical Short Interest Coherus BioSciences Short Interest Corbus Pharmaceuticals Short Interest Pliant Therapeutics Short Interest Ventyx Biosciences Short Interest Senti Biosciences Short Interest Galectin Therapeutics Short Interest Adagene Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:OTLC) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncotelic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncotelic Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OTLC Stock Free OTLC Stock Alerts